JW Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
JW Pharmaceutical has a total shareholder equity of ₩303.8B and total debt of ₩109.2B, which brings its debt-to-equity ratio to 35.9%. Its total assets and total liabilities are ₩636.9B and ₩333.1B respectively. JW Pharmaceutical's EBIT is ₩97.4B making its interest coverage ratio 18.5. It has cash and short-term investments of ₩95.9B.
Key information
35.9%
Debt to equity ratio
₩109.17b
Debt
| Interest coverage ratio | 18.5x |
| Cash | ₩95.91b |
| Equity | ₩303.77b |
| Total liabilities | ₩333.11b |
| Total assets | ₩636.88b |
Recent financial health updates
JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly
Aug 07
Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?
Feb 15Recent updates
JW Pharmaceutical's (KRX:001060) Solid Earnings May Rest On Weak Foundations
Nov 23JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly
Aug 07JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality
Mar 21Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?
Apr 08How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?
Mar 13Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?
Feb 15JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.
Jan 19
Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend
Dec 24Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?
Nov 30Financial Position Analysis
Short Term Liabilities: A001060's short term assets (₩361.0B) exceed its short term liabilities (₩254.8B).
Long Term Liabilities: A001060's short term assets (₩361.0B) exceed its long term liabilities (₩78.3B).
Debt to Equity History and Analysis
Debt Level: A001060's net debt to equity ratio (4.4%) is considered satisfactory.
Reducing Debt: A001060's debt to equity ratio has reduced from 77.3% to 35.9% over the past 5 years.
Debt Coverage: A001060's debt is well covered by operating cash flow (87.1%).
Interest Coverage: A001060's interest payments on its debt are well covered by EBIT (18.5x coverage).